CSPC Pharmaceutical Group Ltd.’s shares logged their biggest decline since Feb. 19 on speculation that a component of the Chinese drugmaker’s key product has been put on a government watch list.
The possible inclusion of the substance, butylphthalide, on the watch list in China’s eastern Zhejiang province would mean the local government would closely monitor its usage.